Facebook
Instagram
Linkedin
Pinterest
Reddit
Twitter
Youtube
Sign in
Home
Safe Snack Guide
Peanut and Tree Nut Free Edition
Milk Free Edition
Sesame Free Edition
Gluten Free Edition
Custom Edition
Allergence
Coupons
About Us
Media Kit
Advertising Guide
Manufacturer Partnership
Subscribe to our newsletter
Put Your School on the Map
Contact Us
Resources
FAQ
Tools for Schools
Coupons
Sign in
Welcome!
Log into your account
your username
your password
Forgot your password?
Terms and Conditions
Password recovery
Recover your password
your email
Search
Home
Safe Snack Guide
Peanut and Tree Nut Free Edition
Milk Free Edition
Sesame Free Edition
Gluten Free Edition
Custom Edition
Allergence
Coupons
About Us
Media Kit
Advertising Guide
Manufacturer Partnership
Subscribe to our newsletter
Put Your School on the Map
Contact Us
Resources
FAQ
Tools for Schools
Coupons
Search
Home
Tags
Sanofi
Tag: Sanofi
Study Finds Biologic Drug Highly Effective in Reducing Pediatric Eczema Symptoms
News Wire ~ 3rd Party Press Release
-
2022/09/19
0
Dupixent® Phase 3 Trial Shows Positive Results in Children Ages 1-11...
News Wire ~ 3rd Party Press Release
-
2022/07/15
0
FDA Accepts Dupixent® (dupilumab) for Priority Review in Patients Aged 12...
News Wire ~ 3rd Party Press Release
-
2022/04/12
0
Sanofi Presses Court Battle with Mylan in Appeal of EpiPen Antitrust...
Dave Bloom
-
2021/06/07
0
FDA Approves Dupixent® as First Biologic for Treatment of Children Aged...
News Wire ~ 3rd Party Press Release
-
2020/05/28
0
Sanofi Seeking Billions from Mylan in EpiPen Antitrust Suit
Dave Bloom
-
2019/08/13
0
FDA Approves Dupixent® (dupilumab) for Moderate-to-severe Atopic Dermatitis in Adolescents
News Wire ~ 3rd Party Press Release
-
2019/03/12
0
Aimmune Therapeutics Announces Initiation of Phase 2 Study of AR101 With...
News Wire ~ 3rd Party Press Release
-
2018/10/15
0
Phase II Trials of AR101 with Dupilumab for Peanut Allergy to...
Dave Bloom
-
2018/09/27
1
Study: Dupilumab Showed Positive Phase 3 Results in Adolescents with Inadequately...
News Wire ~ 3rd Party Press Release
-
2018/05/17
0
1
2
3
Page 1 of 3